Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Dec:2:1-14.
doi: 10.1200/CCI.17.00083.

American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives

Affiliations
Review

American Association for Cancer Research Project Genomics Evidence Neoplasia Information Exchange: From Inception to First Data Release and Beyond-Lessons Learned and Member Institutions' Perspectives

Christine M Micheel et al. JCO Clin Cancer Inform. 2018 Dec.

Abstract

The American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) is an international data-sharing consortium focused on enabling advances in precision oncology through the gathering and sharing of tumor genetic sequencing data linked with clinical data. The project's history, operational structure, lessons learned, and institutional perspectives on participation in the data-sharing consortium are reviewed. Individuals involved with the inception and execution of AACR Project GENIE from each member institution described their experiences and lessons learned. The consortium was conceived in January 2014 and publicly released its first data set in January 2017, which consisted of 18,804 samples from 18,324 patients contributed by the eight founding institutions. Commitment and contributions from many individuals at AACR and the member institutions were crucial to the consortium's success. These individuals filled leadership, project management, informatics, data curation, contracts, ethics, and security roles. Many lessons were learned during the first 3 years of the consortium, including on how to gather, harmonize, and share data; how to make decisions and foster collaboration; and how to set the stage for continued participation and expansion of the consortium. We hope that the lessons shared here will assist new GENIE members as well as others who embark on the journey of forming a genomic data-sharing consortium.

PubMed Disclaimer

Conflict of interest statement

Christine M. Micheel

Consulting or Advisory Role: Roche

Shawn M. Sweeney

No relationship to disclose

Michele L. LeNoue-Newton

Employment: DaVita (I)

Fabrice André

Research Funding: AstraZeneca (Inst), Novartis (Inst), Pfizer (Inst), Eli Lilly (Inst)

Travel, Accommodations, Expenses: Novartis, Roche, GlaxoSmithKline, AstraZeneca

Philippe L. Bedard

Research Funding: Bristol-Myers Squibb (Inst), Sanofi (Inst), AstraZeneca (Inst), Genentech (Inst), Roche (Inst), Servier (Inst), GlaxoSmithKline (Inst), Novartis (Inst), SignalChem (Inst), PTC Therapeutics (Inst), Cascadian Therapeutics (Inst), Nektar (Inst)

Justin Guinney

Research Funding: Celgene (Inst)

Gerrit A. Meijer

Research Funding: Royal Philips (Inst), GlaxoSmithKline (Inst), Keosys SAS (Inst), OpenClinica (Inst), Roche Diagnostics Nederland (Inst), Exact Sciences (Inst), Genalice (Inst), The Hyve (Inst), OpenText (Inst), SURFsara (Inst), Vancis (Inst), Computer Sciences Corporation (Inst), Sysmex (Inst), Sentinel Diagnostics (Inst)

Patents, Royalties, Other Intellectual Property: Several patents pending (Inst)

Barrett J. Rollins

No relationship to disclose

Charles L. Sawyers

Leadership: Novartis

Stock and Other Ownership Interests: Novartis, Agios Pharmaceuticals, Blueprint Medicines, BeiGene, ORIC Pharmaceuticals

Consulting or Advisory Role: Novartis, Blueprint Medicines, Agios Pharmaceuticals, BeiGene, ORIC Pharmaceuticals

Patents, Royalties, Other Intellectual Property: Xtandi (Astellas Pharma, Medivation)

Nikolaus Schultz

No relationship to disclose

Kenna R. Mills Shaw

No relationship to disclose

Victor E. Velculescu

Leadership: Personal Genome Diagnostics

Stock and Other Ownership Interests: Personal Genome Diagnostics, Ignyta

Consulting or Advisory Role: Quintiles, Janssen Pharmaceuticals, Ignyta, Personal Genome Diagnostics

Patents, Royalties, Other Intellectual Property: Receive royalties for discoveries our group has made at Johns Hopkins that have been licensed by QIAGEN. Receive royalties for discoveries our group has made at Johns Hopkins that have been licensed by Myriad. Receive royalties for discoveries our group has made at Johns Hopkins that have been licensed by Personal Genome Diagnostics. Receive royalties for discoveries our group has made at Johns Hopkins that have been licensed by Genzyme. Receive royalties for discoveries our group has made at Johns Hopkins that have been licensed by Roche.

Mia A. Levy

Employment: SeqTech Diagnostics (I)

Leadership: Personalis

Consulting or Advisory Role: Personalis, GenomOncology

Figures

Fig 1.
Fig 1.
American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE) timeline. AACR Project GENIE has developed rapidly from an initial concept in early 2014 to a formal business plan and approval by the AACR board of directors in January 2015. The consortium meets twice a year in January and July. Other notable dates are the November 2015 public launch, the October 2016 data freeze meeting, and the January 2017 first public release of data.
Fig 2.
Fig 2.
Organization of American Association for Cancer Research (AACR) Project Genomics Evidence Neoplasia Information Exchange (GENIE). The project is led by a steering committee that reports to the AACR board of directors and receives guidance from an external advisory board. Four subcommittees that make recommendations about various processes report to the steering committee, as does the AACR Project GENIE coordinating center. Project GENIE is executed in collaboration with two strategic partners: Sage Bionetworks and cBioPortal. CEO, chief executive officer; CTCRC, Clinical and Translational Cancer Research Committee; SPGA, Science Policy and Government Affairs.
Fig 3.
Fig 3.
Technology and architecture, which shows how data flow in the consortium, including the location of data and the technologies used. GENIE, Genomics Evidence Neoplasia Information Exchange; NGS, next-generation sequencing; REDCap, Research Electronic Data Capture.
Fig 4.
Fig 4.
Overview of the Genomics Evidence Neoplasia Information Exchange (GENIE) version 1.0.1 data set. (A) The top 12 mutated genes, (B) copy number alterations, (C) major cancer types, and (D) cancer subtypes from the first public data release are plotted.

Similar articles

Cited by

References

    1. AACR Project GENIE Consortium : AACR Project GENIE: Powering precision medicine through an international consortium. Cancer Discov 7:818-831, 2017 - PMC - PubMed
    1. Lawrence MS, Stojanov P, Mermel CH, et al. : Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 505:495-501, 2014 - PMC - PubMed
    1. The AACR Project GENIE Consortium : AACR GENIE Data Guide, 2017. http://www.aacr.org/Research/Research/Documents/GENIE%20Data%20Guide.pdf
    1. The AACR Project GENIE Consortium : AACR Project GENIE Participation Evaluation Criteria, 2017. http://www.aacr.org/Documents/GENIE_New_Participant_Criteria.pdf
    1. Derry JM, Mangravite LM, Suver C, et al. : Developing predictive molecular maps of human disease through community-based modeling. Nat Genet 44:127-130, 2012 - PMC - PubMed

Publication types